Piroxicam

This classification denotes a cyclooxygenase inhibitor and aromatic compound with the molecular formula C15H13N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13T4O6VMAM, chemically known as 4-hydroxy-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide but generally known as piroxicam, which bears US NIH Compound Identifier 5280452. European Medicines Agency schedules Piroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09936MIG. The term PIROXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules piroxicam in its Anatomical Therapeutic Chemical (ATC) Classification. PIROXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piroxicam under HS 29349990 and SITC 51579. As of Q4 2014, PIROXICAM remains the US FDA Preferred Term for this commodity. Piroxicam bears US NLM identifiers UMLS ID C0031990 and NCI Concept Code C751. SMILES: S1(=O)(=O)N(/C(=C(/O)NC2NCCCC2)C(=O)C2C1CCCC2)C.